Mumbai, June 4 -- Aurobindo Pharma has received a final approval from the US Food

& Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets, 5 mg and 10 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xeljanz Tablets, 5 mg

and 10 mg, of PF Prism C.V.

The product will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company and will be launched immediately.

Published by HT Digital Content Services with permission from Capital Market....